Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib 140mg QD vs 70mg BID in Advanced CML and Ph+ ALL
NCT00123487Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2005
- Primary completion
- Nov 2006
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 32
01
Overview
Phase 3, randomised, open-label trial of dasatinib in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Percent of Participants With Major Hematologic Response (MaHR) at 6 months. Started Jun 2005; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00123487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123487.